Soleno Therapeutics resumed with a Buy at Stifel

Stifel resumed coverage of Soleno Therapeutics (SLNO) with a Buy rating and $74 price target A PDUFA deadline in Prader-Willi is set for March 27, notes the analyst, who ultimately thinks DCCR gets approved, pegging the odds of success at 80%. The data, while not “pristine,” collectively establish a credible clinical effect that, with a favorable risk/benefit in a rare disease with significant unmet need, should support approval, the analyst tells investors.